Le Gouill S, Dlugosz-Danecka M, Rule S, Zinzani PL, et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica 2023 Jul 20. doi: 10.3324/haematol.2022.282469.
PMID: 37470152